Pregnancy and Postpartum CGM in GDM

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorIcahn School of Medicine at Mount Sinai

About this trial

Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Eligibility criteria

Qualifiers

Diagnosis of gestational diabetes during current pregnancy

age 18 or older

prescribed Dexcom G7

Disqualifiers

Pregestational diabetes

known skin adhesive allergy which inhibits ongoing use of CGM

chronic oral steroid use.

Trial design

Treatments tested in this trial

  • continuous glucose monitor

Treatment groups

40 Participants
are divided into 1 treatment group